Navigation Links
Cancer Mortality Increases With Cancer Cell Replikin Count

Drs. Samuel and Elenore Bogoch of Oncolab, Inc. have found that the concentration of replikins, a new class of peptides in genomic proteins*, are quantitatively related to the mortality rate in human cancer of different cell types. No cancer cell genomic structure has previously been reported to be quantitatively related to mortality rate.

Boston, MA (PRWEB) December 4, 2008 -- Drs. Samuel and Elenore Bogoch of Oncolab, Inc. have found that the concentration of replikins, a new class of peptides in genomic proteins*, are quantitatively related to the mortality rate in human cancer of different cell types. No cancer cell genomic structure has previously been reported to be quantitatively related to mortality rate.

The attached figure shows the relationship between the Replikin Count™ in the Replikin Peak Gene* and the percent mortality in human cancer: the higher the Replikin Count, the higher the percent mortality after 5 years.  Glioblastoma multiforme and non-small-cell lung cancer, the two cancer cell types with the greatest 5-year mortality rates in 2002 (98% and 91% respectively), are also the cell types which have the highest Replikin Counts (325 and 250 respectively).
The count in Glioblastoma Multiforme is 18 times higher than the counts in prostate and thyroid cancer which have the lowest Replikin Counts (20 and 15 respectively) as well as the lowest 5-year mortality rates (each approximately 2%). The quantitative relationship of Replikin count to mortality is also seen in the figure for other common cancers, which shows some deviations from an 'ideal' curve. For example, gastric cancer has a higher mortality rate than expected from its Replikin Count (ie shifted to the right), possibly because of the known difficulty of early detection of gastric cancer. Breast and urinary bladder cancer have lower mortality rates than expected from their Replikin Counts (ie shifted to the left), possibly because of the improvement in their early detection and prompt treatment.
To obtain these results, all cancer protein sequences published on PubMed were analyzed by histological cancer cell type by ReplikinForecast™ software. The Replikin Peak Gene (RPGene)* was identified in each cell type. The replikins in each RPGene were counted (Replikin Count = number of replikins per 100 amino acids).  The Replikin count of each RPGene then was compared in the different histological cancer cell types as shown in the attached Figure.
Replikin count has already been shown by Replikins, Ltd. to be related to rapid replication, disease outbreaks, and host mortality in viruses such as influenza and HIV, bacteria, malaria, and other infectious diseases*. The relationship between Replikin count and mortality in cancer parallels that found in H5N1 virus in humans and in Taura Syndrome Virus in shrimp.
The authors speculate that in low mortality cancers, it is possible that the immune system may be adequate to the number of invading units; but that the increased mortality rate in viruses and in cancer may reflect the overwhelming of host immune defenses by markedly increased numbers of viruses or of cancer cells produced in each case by increasing replikin concentration in the up-regulated Replikin Peak Gene.  An increase in number of cancer cells per unit time produced by rapid replication has been demonstrated in the laboratory in the case of glioblastoma multiforme brain cancer cells in tissue culture*. The quantitative relationship of Replikin Count to mortality rate has been demonstrated in the laboratory in four strains of lethal Taura Syndrome Virus in shrimp*.
These findings have diagnostic, therapeutic, and preventive applications. On the diagnostic side, 1) Oncolab, Inc.'s AMAS®Test, FDA permitted to market and Medicare approved, measures an anti-replikin antibody called the antimalignin antibody useful in the early detection of cancer. 2) Oncolab is now developing a test to determine the lethality of cancer specimens with the use of ReplikinsForecast™ to analyze the replikins in cancer cell protein sequences.  Encouraged by the proof of principle demonstration that synthetic replikin vaccines can be effective (91% of shrimp who received an oral synthetic replikin vaccine survived lethal Taura Syndrome virus challenge), synthetic replikin cancer vaccines are currently in development.
For published detailed antimalignin antibody data by Oncolab,Inc. and the replikins data of Replikins Ltd. studies,  see For summaries see under "Replikins Press" and  Contacts: Oncolab, Inc. 617-536-9711; Replikins, Ltd. 617-536-0220.

# # #

Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Molecular Breast Imaging Outperforms MRI for Patients With Inconclusive Results in the Diagnosis of Cancer
2. Molecular Breast Imaging Identifies Occult Cancer
3. Medicsight PLC Presents New Data at RSNA 2008 Further Supporting Relevance of Computer-Aided Detection (CAD) and Image Analysis Software in Early Colon Cancer Screening and Diagnosis
4. Prostate Cancer Stimulates Nerve Growth
5. Researchers discover new enzyme in cancer growth
6. International study supports new standard of treatment for women with advanced ovarian cancer
7. Genetic breakdown in Fanconi anemia may have link to HPV-associated cancer
8. Broccoli compound targets key enzyme in late-stage cancer
9. Prostate cancer drug reduces testosterone levels in as little as 3 days
10. More High-Risk Women Preempt Breast Cancer
11. New breast imaging technology targets hard-to-detect cancers
Post Your Comments:
Related Image:
Cancer Mortality Increases With Cancer Cell Replikin Count
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/7/2017)... 2017   Provista, a proven leader in ... in purchasing power, today announced a new resource area ... Newsroom is the online home for case studies, ... bios, news releases, slideshows and events. ... of resources at their fingertips, viewers can also watch ...
Breaking Medicine Technology: